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Abstract
Chagas’ disease or American trypanosomiasis, is a potentially lethal parasitic zoonosis preva-
lent and endemic only in Latin America, caused by the flagellate protozoa Trypanosoma cruzi.
It has 3 differents stages, acute, indeterminate and chronic phase, with the chance of an
etiological approach in the first stage and pharmacological and non-pharmacological treat-
ment in the chronic phase. There are five main clinical forms of chronic chagasic cardiomyo-
pathy: indeterminate, arrhythymogenic (predominantly dromotropic and extrasystolic), with
ventricular dysfunction, thromboembolic and mixed forms. There are several diagnostic tests
at the different stages, however, the ECG is the method of choice in longitudinal population
studies in endemic areas because it is simple, with a low cost and a good sensitivity. Micro-
scopic examination or parasitological diagnosis in the acute phase or immunodiagnostic tests
are used to confirm the disease. The antiarrhythmic drug amiodarone, the most frequently
prescribed agent for symptomatic ventricular arrhythmia treatment of Chagas’ disease pa-
tients, has also recently been shown to have antifungal activity. Cardiac device implantation
is very common, and chronic Chagas disease patients require pacemaker implantation at
a younger age in contrast with patients with other cardiac pathologies. In summary, Chagas
disease is a social disease, endemic in Latin America and shows different prevalence rates in
Latin American countries. (Cardiol J 2008; 15: 493–504)
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Introduction
Chagas’ disease or American trypanosomiasis,
is a potentially lethal parasitic zoonosis prevalent
and endemic only in Latin America. The entity con-
stitutes and important public health problem in most
of the Latin American countries. The illness is caused
by the flagellate protozoa Trypanosoma cruzi (T. cruzi).
This parasite belongs to the Kinetoplastida order
and the Trypanosomatidae family. It has several vul-
gar names: vinchuca, barbeiro, kissing bug, cone-
nosed bug, chupança, chinchorro and benchuca.
The disease has an incubation or asymptoma-
tic period followed inconstantly by tree clinical sta-
ges: acute or primary infection, undetermined or
latent phase and chronic stage.
Incubation or asymptomatic period
Incubation period lasts approximately seven to
ten days in cases of vectorial contamination becau-
se metacyclic trypanomastigotes are more active.
In these cases, the infection is transmitted via the
feces of blood-sucking insect vectors (wild cycle)
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and human disease results from the colonization of
the human habitat by some vector species (dome-
stic cycle).
Incubation period duration is one month in cases
of transfusion contamination because circulating try-
pomastigotes have lesser capacity to invade the cells.
The three clinical stages
Acute phase, primary infection, or first stage
Defined as the phase in which detection of blo-
od parasites is possible, lasting from 1–3 months [1].
This stage occurs unrecognized in most cases and
clinically apparent acute chagasic myocarditis may
appear in less than 5% of the infected individuals,
usually children living in endemic areas. The majo-
rity of the cases of acute myocarditis are mild and
reversible. Autopsied cases of acute chagasic my-
ocarditis are uncommon and correspond to excep-
tionally severe or fulminant forms showing diffuse
myocardial damage with myocytolysis, degenerati-
ve changes of myocardial fibers and marked inter-
stitial cellular infiltration. The mortality during the
acute phase of cardiac Chagas’ disease is around 5%
of the cases and it is mostly related to myocarditis.
The acute clinical manifestations of the infected
individuals include fever, rash, lesion at the site of
entry (Chagoma), muscular pain, sweating, swollen
lymph nodes, hepatosplenomegaly, subcutaneous
edema localized or generalized (40% of cases), me-
ningitis sigs, acute myocarditis and bronchopneu-
monitis [2]. These non-specific symptoms may
often be confused with those of other common chil-
dhood illnesses. Specific anti-Chagasic therapy with
trypanocide drugs is effective in acute phase [3].
Indeterminate stage or latent phase
A majority of the patients with Chagas’ dise-
ase remain in the latent phase of disease for 10 to
30 years or even for life. The indeterminate stage
begins between eight to ten weeks after the initial
infection and may last for many years. In this stage
people do not have symptoms and can carry the
parasite for years without knowing it. About
20–30% of those infected will go on to develop the
chronic form of the disease up to 10 or 30 years after
they first contracted it. The ajmaline test and the
endomyocardial biopsy are, probably, the most sen-
sitive methods to unmask latent forms of chagasic
myocarditis during the indeterminate stage [4].
Chronic phase
Myocardial involvement in this stage might
present as cardiac autonomic dysfunction, myocar-
dial apoptosis, and myocardial fibrosis. This phase
is mainly attributed to neuronal damage induced by
immune and inflammatory processes elicited by the
presence of T. cruzi.
Symptoms of biventricular heart failure are fre-
quently observed with peripheral edema, hepato-
megaly, and thromboembolic events.
Chronic Chagasic cardiomyopathy is an entity
with several components: fibrosis, necrosis, vascu-
lopathy, immunopathy, autonomic dysfunction, ac-
cumulative, progressive and diffuse myocarditis. It
is characterized by [5]:
— parasite-dependent myocardial damage
with reparative and reactive interstitial fibro-
sis. The cardiac conduction system is frequ-
ently damaged at numerous sites, the lesions
including focal inflammatory infiltration with
lymphocytes and extensive focal fibrotic de-
generation in neighboring regions. These le-
sions involve myocytes, nerves and blood ves-
sels [6];
— microvascular disturbances including ne-
crotizing microvascular arteritis that leads to
platelet thrombosis and subsequent hypoper-
fusion and foci of myocytolytic necrosis, which
progressively destroy both myocardial contrac-
tile cells (myocytolysis) and the pacemaking/
/conduction system;
— immune-mediated myocardial injury due to
cross-over autoimmune reaction, triggered
against the MXT antigen of T. cruzi, which is
homologous to myosin of cardiac structures;
— autonomic nervous system derangements
of focal character, irregular distribution, varia-
ble and unpredictable;
— extra-cardiac manifestations include visce-
romegalies that are the most important dige-
stive system manifestations of Chagas disease
and characterized by motor disorders and dila-
tion of organs such as esophagus and colon [7].
Classification of cardiac
forms of Chagas disease
There are five main clinical forms of chronic
chagasic cardiomyopathy: indeterminate, arrhy-
thymogenic (predominantly dromotropic and pre-
dominantly extrasystolic), with ventricular dysfunc-
tion, thromboembolic and mixed forms.
— Chronic indeterminate Chagas’ disease:
The indeterminate form of Chagas’ disease is
defined by the absence of clinical, radiological
and electrocardiographic manifestations of car-
diac or digestive involvement in persons with
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T. cruzi chronic infection. When submitted to
advanced cardiovascular tests, these patients
may present significant abnormalities [8]. The
serum positive subjects have significantly hi-
gher serum concentrations of tumor necrosis
factor (TNF) and nitric oxide (NO) than the
controls and the cases of chronic Chagas dise-
ase have significantly higher serum concentra-
tions of TNF and NO than the subjects with the
indeterminate form of the disease. It therefo-
re appears that the host’s anti-oxidant respon-
ses (at least in terms of elevated concentrations
of superoxide dismutase (SOD) a prime anti-
oxidant enzyme, may inhibit inflammation during
the indeterminate phase of Chagas’ disease;
— Arrhythmogenic:
— dominant conduction defects: characteristic
complete right bundle branch block (com-
plete RBBB) associated with left anterior
fascicular block (LAFB);
— dominant polymorphic premature ventricu-
lar contractions (PVCs) and/or ventricular
tachycardia (VT). In implantable cardiover-
ter defibrillator (ICD) recipients with Cha-
gas cardiomyopathy, spontaneous mono-
morphic VT episodes are typically initiated
by late-coupled PVCs, which often show
a short-long-short sequence [9];
— both phenomena together;
— With ventricular dysfunction: Chronic di-
lated chagasic cardiomyopathy.
— Thromboembolic forms: Cardiac arrhythmias,
congestive heart failure, apical aneurysm and
mural thrombus are potential embolic factors
that partially explain the genesis of chagasic
stroke and pulmonary embolism. Chagasic car-
diomyopathy is a neglected, frequently unreco-
gnized, source of embolic stroke in South Ame-
rica [10]. It has also been termed “emboligenic
cardiomyopathy” since arterial embolism is
a very frequent complication. Embolic obstruc-
tion of a coronary artery may therefore well be
the most probable cause of myocardial infarc-
tion in young people with Chagas’ disease;
— Mixed forms: These cases present features
of two or more forms described above.
Transmission modes of human disease
— Vectorial transmission via the feces of Triato-
ma represents 80% of cases. Under natural
conditions, T. cruzi is transmitted by insects
belonging to different species of Triatoma. An
infected triatomine insect vector feeds on blo-
od and releases trypanomastigotes in its feces
near the site of the bite wound;
— Transfusion of infected blood (5% to 20% of ca-
ses) [11]. Blood donor education, identification
of putatively infected blood donors by question-
naire or serological screening tests, and me-
thods of parasite inactivation may significantly
reduce the transmission of T. cruzi by alloge-
neic blood transfusions [12].
— Transplacentary or congenital transmission
from pregnant woman to her baby: 2% to 10%
of cases. Serological screening of pregnant wo-
men by rapid diagnostic tests and examination
of babies born from serum positive mothers by
hematocrit method at birth is a suitable stra-
tegy to detect and prevent congenital Chagas
disease in non-endemic areas [13, 14].
— Oral transmission: consumption of uncooked
food contaminated with feces of infected bugs.
T. cruzi infection by oral route constitutes the
most important mode of transmission in some
geographical regions, as illustrated by reports on
microepidemics and outbreaks of acute Chagas’
disease acquired by ingestion of food contamina-
ted with parasites from triatomine insects [15].
— Organ transplantation [16]. Chagas disease fol-
lowing solid-organ transplantation has occur-
red in Latin America, an in 2002 in the United
States [17]. In areas of U.S. where there is
a high number of immigrants from T. cruzi ende-
mic countries, screening for anti-Trypanosoma
cruzi donor antibodies may be beneficial [18].
— Accidental laboratory exposure [19].
Epidemiological aspects
The disease is endemic in Latin America, from
the north of Mexico to the South of Argentina and
Chile. The number of people with Chagas’ disease
worldwide is estimated to be about 16–18 million
in 18 countries of Latin America [20]. There are
90,000,000 exposed and 120,000 new cases per year
diagnosed in Latin America.
Mortality is around 45.000 to 50.000 people/
/year and the main cause of mortality is cardiac car-
diomyopathy:
— ª 60% sudden cardiac death. Rarely, it may be
the first manifestation of Chagas’ disease. The
causes are:
— ventricular fibrillation (VF),
— bradyarrhythmia,
— thromboembolism,
— rarely aneurysm rupture;
— ª 30% congestive heart failure;
496
Cardiology Journal 2008, Vol. 15, No. 6
www.cardiologyjournal.org
— ª 15% cerebral or pulmonary embolism;
— others (ª 5%) include severe acute myocardi-
tis, meningoencephalitis in the newborn, volvu-
lus of he dilated sigmoid megacolon.
Prevalence in endemic
Latin American countries
The Table 1 shows the different prevalence
rates in Latin American countries.
It is estimated that ª 25% of individuals infec-
ted with T. cruzi will develop symptomatic heart
disease at some point during their lives.
The beetles that transmit Chagas live in cracks
in the walls and roofs of mud and straw housing,
which are common in rural areas and poor urban
slums in Latin America. Population movements
from rural to urban areas in the 1970s and 80s bro-
ught Chagas’ disease into cities, and it became an
urban infection transmitted through blood transfu-
sions. Blood banks reported T. cruzi infection ra-
tes ranging from 1.7% in Sao Paulo, Brazil, to 53%
in Santa Cruz, Bolivia, where Chagas infection ra-
tes far exceeded those of HIV infection and hepati-
tis. Chagas disease is most common among the
poorest and most vulnerable populations. Treat-
ment of the disease has been systematically sideli-
ned by national and regional health authorities.
Spain
In Barcelona, the immigrant population from
Latin America with risk factors for American try-
panosomiasis were screened for Chagas disease by
immunofluorescence assay and 34% had positive
tests [21].
USA
It is estimated that 100.00–675.000 immigrants
from México and Central and South America are
infected. In 2006, the first human case of insect-trans-
mitted Chagas parasite in Louisiana was discovered
[22] and there had only been five reported previously.
The blood just began to be screened for the Chagas
parasite in the U.S. in 2007. Actually, there are signi-
ficant numbers of infected blood units identified.
Switzerland
Several cases have been recently diagnosed in
Switzerland, where systematic screening of groups
at risk should be implemented. As the vast majority
of persons at risk belong to marginalized communities
with limited access to health care, systematic screening
and treatment of infected individuals represent a ma-
jor challenge in order to interrupt the congenital trans-
mission and improve the long-term prognosis [23].
Diagnostic methods
Laboratory tests
— microscopic examination or parasitological
diagnosis (utility in the acute phase):
— fresh anticogulated blood,
— thin and thick blood smears stained with
Giemsa,
— inoculation into mice,
— culture in specialized media (NNN, LIT),
— xenodiagnosis;
— immunodiagnostic test:
— complement fixation test, Guerreiro-
-Machado reaction: an indirect method of
laboratory diagnosis of American trypano-
somiasis. When positive, this test remains
so throughout life, thus being a good indi-
cator of previous infection,
— indirect hemaglutination,
— indirect fluorescent assay (IFA),
— radio-immunoassay (RIA),
— enzyme-linked immunosorbent assay (ELISA).
— molecular biology techniques: polymerase
chain reaction (PCR): it is a diagnostic tool
for congenital Chagas’ disease. Comparative
analysis between both parasitological methods,
on samples taken at birth, showed a higher
sensitivity of PCR as compared to the micro-
hematocrit [24].
Specific tests
Non-invasive cardiologic test:
— electrocardiogram,
— vectorcardiogram,
Table 1. Different prevalence rates in Latin
American countries.
Country Infection prevalence rate
Bolivia 20% of population
Argentina 5–10%
Paraguay 5–10%
Honduras 5–10%
El Salvador 5–10%
Chile 1–5%
Colombia 1–5%
Equator 1–5%
Uruguay 1–5%
Brazil 1.3%
Mexico < 1%
Nicaragua < 1%
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— chest X-ray,
— ambulatory ECG recording,
— cardiopulmonary metabolic exercise test,
— signal-averaged electrocardiogram,
— heart rate variability (HRV) or 24-hour HRV,
— QT-interval dispersion (QTd) [25, 26],
— T-wave alternans (TWA),
— transthoracic echocardiogram (TTE),
— transesophageal echocardiography (TEE) [27],
— real-time three-dimensional (3D) echocardio-
graphy (RT3DE),
— cardiac magnetic resonance imaging (MRI),
gallium-67 myocardial uptake: it is an accurate
and alternative method for the diagnosis of in-
flammatory process associated with chronic
Chagas’ cardiomyopathy [28].
Invasive cardiologic tests:
— electrophysiologic study with His Bundle recor-
ding. In chronic Chagasic cardiomyopathy among
the electrophysiological findings, only the HV in-
terval ≥ 70 ms is associated with cardiovascular
events [29],
— electrophysiological programmed stimulation (EPS),
— endomyocardial biopsy (EMB).
Non-invasive non-cardiologic test:
— radiographic contrast study of the esophagus,
— radiographic study of the colon,
— radiographic contrast studies of the colon,
— esophageal endoscopy and manometry.
Importance of ECG in chronic
Chagasic disease diagnosis
The ECG is the method of choice in longitudi-
nal population studies in endemic areas because it
is simple, with a low cost and a good sensitivity. The
patient newly diagnosed with Chagas disease sho-
uld undergo a medical history, physical examination,
and resting 12-lead ECG with a 30 s lead II rhythm
strip. If this evaluation is normal, no further testing
is indicated; history, physical examination, and ECG
should be repeated annually. If findings suggest
Chagas heart disease, a comprehensive cardiac eva-
luation, including 24-hour Holter monitoring, echocar-
diography, and exercise testing, is recommended [30].
The ECG changes in chronic chagasic cardio-
myopathy have prognostic value.
Rhythm. Sinus node dysfunction is manifested
by persistent sinus bradycardia, sinoatrial (SA) node
block of different degrees, sinus arrest and inappro-
priate chronotropic response in stress test. The cor-
rected recovery time of the SA node and SA con-
duction time are frequently altered (18% to 30%).
Chronic Chagas disease’s patients with sinus node
dysfunction had higher prevalence of muscarinic
agonist antibodies, independent of the presence of
myocardial dysfunction [31].
Dromotropic alterations in the conduction
system. The incidence of second degree type I or
II block, trifascicular block and even total atrioven-
tricular (AV) block are high.
The most frequent are cases of the first degree
AV block, with broad QRS, which in 50% of cases
are located in the AV node and the rest in the His-
-Purkinje system or in both.
Complete RBBB + LAFB, negative T wave
and polymorphic PVCs are typical of Chagasic car-
diomyopathy and occur in 25% of patients.
In the developed countries, the most important
cause of left anterior fascicular block is coronary
insufficiency, particularly the proximal involvement
of the left anterior descending coronary artery, and
in Latin America, Chagas disease [32].
Sustained VT (S-VT) or non sustained VT
(NS-VT). The most frequent location of VT are infe-
ro-posterior and lateral regions, followed by septal and
apical regions, and their main mechanism is reentry,
involving fibrotic and/or aneurysmatic areas [33].
Risk markers of poor prognosis in chronic Cha-
gasic heart disease:
— atrial fibrillation or flutter;
— complete RBBB and decreased ejection fraction;
— complete AV block;
— presence of anterior and inferior electrically in-
active area;
— polymorphic PVCs or salvoes;
— NS-VT associated to decreased ejection frac-
tion: mortality rate reached 80% in 13 years of
follow up;
— presence of S-VT: mortality is close to 100%
in five years.
Typical ECG of chronic Chagasic
heart disease (Fig. 1)
Electrocardiographic diagnosis:
— P wave: difficult to visualize, which indicates
intense fibrosis of atrial tissue;
— LAFB: extreme shift of QRS axis in the left
superior quadrant, around –75°, qR pattern in
I and VL, rS pattern in inferior leads with final
broad S wave in V5 and V6;
— complete RBBB: triphasic QRS complex, rsr’
type, from V1 to V3, broad final r wave in VR
and wide final S wave in V5 and V6;
— coupled PVCs;
— classical triad: complete RBBB + LAFB +
+ polymorphic PVCs.
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ECG/VCG correlation (Fig. 2)
— Frontal plane typical QRS loop with LAFB
pattern;
— Horizontal plane typical complete RBBB Grish-
man type (afferent limb of QRS loop located
behind the X line);
— Final end conduction delay located in the right
anterior quadrant;
— T loop directed to backwards;
— Clinical diagnosis: chronic Chagasic heart di-
sease, dromotropic form;
— Echocardiographic diagnosis: telesystolic
prolapse with mild escape;
Figure 1. Typical ECG of chronic Chagasic heart disease.
Figure 2. ECG/VCG correlation; CRBBB — complete right bundle branch block; LAFB — left anterior fascicular block.
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— Ejection fraction: 73%;
— ECG diagnosis: heart rate: 77 bpm, P wave
difficult to visualize in the frontal plane. The
difficult visualization of P wave in the FP may
indicate a certain degree of atrial wall fibrosis
(sinoventricular conduction); PR interval: 200
ms; SAQRS –70o; QRS duration: 150 ms; Rs
pattern from V2 to V6.
— Conclusion: complete RBBB + LAFB + pro-
minent anterior forces (PAF) (Fig. 3)
ECG/VCG correlation:
Frontal plane (Fig. 4)
— QRS loop with counterclockwise rotation and
extreme left axis deviation;
Figure 3. Clinical diagnosis: chronic Chagasic heart disease, dromotropic form.
Figure 4. ECG/VCG correlation — frontal plane; CRBBB — complete right bundle branch block; LAFB — left anterior
fascicular block; RECD — right end conduction delay.
Name: OO Age: 51 years old Weight: 71 kg Date: 04/19/2004
Sex: Male Ethnic: Asian Height: 1.679 m Medication in use: None stated
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— rS or rSr´ pattern in inferior leads with SIII > SII:
LAFB;
— End conduction delay located near right portion
(±180o) of X orthogonal leads: complete RBBB.
ECG/VCG correlation:
Horizontal plane (Fig. 5)
— Typical pattern of complete RBBB Grishman
type; right end conduction delay located on right
anterior quadrant with “glove finger” shape;
— PAF form V1 to V4;
— T loop directed backwards and leftwards.
Prognosis
Independent prognostic factors identified in
chronic Chagas cardiomyopathy:
— depressed left ventricular ejection fraction
< 50%;
— VT at Holter monitoring or stress testing;
— SAECG: prolonged (> 150 ms) filtered QRS
complex duration [34];
In patients with chronic systolic heart failure
in the course of Chagas’ disease predictors of all-
cause mortality include:
— New York Heart Association (NYHA) class IV
on admission;
— lack of beta-blocking agent use;
— serum sodium levels;
— digoxin treatment [35].
Chagas’ risk index (Table 2) [36]
A systematic review of published studies indi-
cates that impaired left ventricular function, NYHA
class III/IV, cardiomegaly on the chest radiography,
and NS-VT indicate a poor prognosis in patients
with chronic Chagas’ disease [37].
Five-year mortality of chronic Chagas’ disease
patients with cardiac dysfunction is above 50%.
Management
Therapeutic armamentarium in cardiac Chaga-
sic disease:
— etiological approach: antiprotozoal;
— hygienic dietetic approach;
— medical treatment of chronic Chagasic heart
failure;
— anticoagulant treatment;
— pharmacological treatment of ventricular
arrhythmias with class III drugs;
Figure 5. ECG/VCG correlation — horizontal plane; PAF — prominent anterior forces; CRBBB — complete right
bundle branch block; LAFB — left anterior fascicular block; RECD — right end conduction delay.
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— permanent pacemaker implantation;
— ICD;
— radiofrequency ablation;
— orthotopic heart transplantation.
Etiological approach: Antiprotozoal
Etiological treatment of Chagas disease is
a controversial issue because the available drugs are
highly toxic. Treatment for Chagas disease is re-
commended for all people diagnosed with an acute
infection, congenital infection, and for those with
suppressed immune systems. Other chronically
infected people (especially children) may benefit
from treatment. The antiparasitic drug, benznida-
zole (5 mg/kg/day), is effective when given for the
initial infection and may also be beneficial for the
chronic phase (recently acquired). Recent data in-
dicate that parasite persistence plays a pivotal role
in the pathogenesis of chronic Chagas’ cardiomyo-
pathy. However, the efficacy of trypanocidal thera-
py in preventing clinical complications in patients
with preexisting cardiac disease is unknown.
The BENEFIT Trial (Evaluation of the Use of
an Antiparasital Drug [Benznidazole] in the Treat-
ment of Chronic Chagas’ Disease) was designed to
determine if 60 days of treatment with benznidazo-
le could prevent the progression of cardiac disease
in patients with Chagas disease.
The BENEFIT study is being conducted by the
Population Health Research Institute (in Hamilton,
Canada) and the Institute Dante Pazzanese de Car-
diologia (Sao Paulo, Brazil) together with an inde-
pendent Steering Committee. The study is an inte-
rventional one and it is a randomized, double-blind,
placebo-controlled, single group assignment, safe-
ty/efficacy study. Up to date, this is the first trial
investigating the use of antiparasitic drugs in pa-
tients that are in the chronic phase.
It will be conducted in 75 study centres in
Argentina, Brazil, Colombia, Venezuela, Peru and
Bolivia — countries with high incidence of Chagas
disease and will include 3,000 patients.
The primary outcome is:
— the composite of death and hospitalization;
— resuscitated cardiac arrest;
— documented S-VT requiring cardioversion;
— insertion of pacemaker or ICD;
— cardiac transplantation;
— new development of symptomatic congestive
heart failure;
— new development of stroke;
— any new thromboembolic event in patients with
no prior thromboembolic phenomena;
— new development of systemic or pulmonary hy-
pertension.
The study started on November 2004, with an
average follow-up time of 5 years, and the trial has
a 90% power to detect a 25% relative risk reduc-
tion. The estimated study completion date is De-
cember 2010.
Medical treatment of chronic
Chagasic heart failure
In patients with chronic Chagas’ cardiomy-
opathy, optimization of treatment with angioten-
sin-converting enzyme inhibitors, furosemide,
spironolactone and subsequent addition of carve-
dilol are safe and associated with benefits in car-
diac function and clinical status. Larger trials are
needed to show effects on mortality and/or hospi-
talization [38].
Pharmacological approach of ventricular
arrhythmias with class III drugs
The antiarrhythmic drug amiodarone, frequen-
tly prescribed for the symptomatic treatment of
Chagas’ disease patients, has also recently been
shown to have antifungal activity. Amiodarone has
direct activity against T. cruzi, both in vitro and in
vivo, and it acts synergistically with posaconazole.
In patients with chagasic cardiomyopathy and S-VT,
electrophysiologic testing can predict long-term effi-
cacy of class III antiarrhythmic drugs. This may help
in the selection of patients for ICD therapy [39, 40].
Permanent pacemaker implantation
Pacemaker implantation may contribute to
a better survival in selected chronic Chagas’ disease
Table 2. Chagas’ risk index.
Risk factor Points
NYHA class III or IV 5
Cardiomegaly ≥ +++ chest X-ray 5
Wall motion abnormalities 3
Non-sustained ventricular 3
tachycardia (NS-VT)
Low voltage on ECG 2
Male gender 2
Total points Risk of death
in 10 years
0–6 10%
7–11 40%
12–20 85%
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patients with cardiac involvement [41]. Chronic
Chagas disease patients require pacemaker implan-
tation at a younger age in contrast with patients with
other cardiac pathologies [42].
Comparison between Chagas and non-Chagas’
disease patients using single or dual-chamber pa-
cemaker in relation to the left ventricular ejection
fraction, the ventricular stimulation threshold and
the occurrence of ventricular arrhythmia show that
these patients are not similar (Table 3) [43].
The principal causes of pacemaker implantation
in this pathology are:
— sinus node dysfunction 57%;
— second and third degree AV block 26%;
— atrial fibrillation with AV block or trifascicular
block [43].
The proportion of implants of single-chamber
devices is bigger than dual-chamber. Frequently the
decision is based on the price of the devices and not
on medical reasons. Anyway, it is necessary to con-
sider that the evolution toward the dilated cardio-
myopathy is common in these patients. In this case
the use of the atrial electrode is crucial. In the se-
lection of the pacemaker type it is necessary to take
into account the autonomic alterations frequently
present in this pathology such as syncope and chrono-
tropic incompetence. The implantation of a DDD-R
system is then mandatory.
Cardiac resynchronization therapy could be
useful in selected cases but since the right bundle
branch block is the most frequent intraventricular
disorder the possibility of improving the ventricu-
lar function has not been completely explored.
On the other hand, Rassi et al. [44] underlined
the importance of rate response function to obtain
a better functional class and reduce the incidence
of ventricular arrhythmias.
This author also suggested that the pacemaker
change the natural evolution of this pathology and
reduce the incidence of sudden death. In the evalu-
ation of risk for sudden death the severe bradyar-
rhythmia due to AV block and/or sinus node dysfunc-
tion are the major predictors together with left ven-
tricular dysfunction, sustained or non sustained
ventricular tachycardia and syncope.
Recomendations for permanent cardiac pacing
in chronic Chagasic cardiomyopathy are similar to
other diseases and where previously published.
Implantable cardioverter-
-defibrillators (ICD)
ICD have sporadically been used in the treat-
ment of either S-VT or VF in Chagas’ disease pa-
tients. The ideal programming of ICD shock ener-
gy should be at least 10 J above the defibrillation
threshold requiring alternative techniques when the
defibrillation threshold is elevated. The occurrence
of elevated defibrillation threshold (> 25 J), leading to
alternative therapies, is low. There is an association
with severe ventricular dysfunction, although witho-
ut correlation to the causes of death [45].
Patients with chronic Chagas’ heart disease
recovered from cardiac arrest have an arrhythmo-
genic profile characterized by a high frequency of
VF and no left ventricular systolic dysfunction and
a short period of time to the first shock [46].
The predictors of all-cause mortality for Cha-
gas’ disease patients receiving ICD therapy are the
number of shocks per patient per 30 days [47].
In Latin America, the experience in secondary
prevention of sudden cardiac death is evaluated by me-
ans of an ongoing registry involving seven Latin Ame-
rican countries and 770 patients, the ICD-LABOR.
Despite the differences in terms of pathologies betwe-
en this trial and randomized ICD trials, a parallel evo-
lution in all cause mortality and cardiac mortality was
observed. Independent risk factors for mortality inc-
luded age > 70 years, male gender, NYHA III/IV, and
ejection fraction < 0.30. The etiology of heart dise-
ase (Chagas disease 26.1% vs. coronary disease
39.7%) was not found to be a risk factor [48].
Table 3. Differences between Chagas and non-Chagas patients in pacemaker recipients.
Chagas´s disease patients Non-Chagas’ disease patients
with permanent pacemaker with permanent pacemaker
Age Younger Older
Left ventricular ejection fraction Lower Higher
Ventricular arrhythmia during Holter monitoring More frequent Less frequent
Prognosis Worse Better
Chest X-ray Similar Similar
Ventricular stimulation threshold Similar Similar
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Radiofrequency ablation
Ventricular tachycardia (VT) is common among
patients with Chagas heart disease but the intrin-
sic mechanisms responsible for its sustained and
nonsustained forms are not completely known. Sa-
rabanda showed that a scar-related reentry was
observed in all patients who underwent endocardial
mapping for attempted radiofrequency ablation. The
localization of the arrhythmia was related to left
ventricular inferolateral scar in most cases (82%).
They also found a significantly higher prevalence
of wall motion abnormalities and myocardial perfu-
sion defects in basal segments more frequent in
patients with sustained ventricular tachycardia than
in non sustained. In conclusion VT may arise from
various regions in both ventricles, but left ventri-
cular inferolateral scar is the main source of susta-
ined VT reentrant circuits [49–50]. The subxypho-
id pericardial mapping approach can be used to fa-
cilitate catheter ablation of Chagasic ventricular
tachycardia. Nonsurgical epicardial transthoracic
catheter ablation is a minimally invasive procedure
that has proven to be efficacious for the treatment
of VT. The usefulness of this technique depends on
the prevalence of epicardial circuits, which seem
more frequent in Chagasic than post-myocardial
infarction VT [51].
For ablation indication, VT must be monomor-
phic, incessant, frequent, refractory to medical tre-
atment with good hemodynamic tolerance. The
technique is better indicated in patients with a ICD
implantation and frequent episodes of ventricular
tachycardia or electric storms. Sosa et al treated
173 patients with this technique, in 65% of them
the approach was endocardial and in 35% epicardial.
The event free survival, around 40% in 5 years, was
better with the combination of epi- and endocardial
mapping [51, 52].
Orthotopic heart transplantation
It is a therapeutic option for patients with end-
stage Chagas’ cardiomyopathy. Reactivation may
occur after transplantation, leading to higher mor-
bidity and graft dysfunction. Events resulting in
greater immunosuppression status contribute to
Chagas’ disease reactivation episodes after heart
transplantation and should alert physicians to make
an early diagnosis and perform pre-emptive thera-
py. Although reactivation leads to a high morbidity
rate, a low mortality rate is observed [53].
Although Chagas’ patients have several diffe-
rent implications when submitted to the transplan-
tation comparing to other etiologies, actually these
difficulties are well known, so treatments and pre-
ventive strategies are also better established. The
most important care is with the immunosuppressi-
ve dosages, which must be different and lower than
used in other pathologies [54].
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